Innate Pharma Dividend

What does Innate Pharma do? The company Innate Pharma SA is a biotechnology company that was founded in 1999 by immunologist Hervé Brailly. The company is headquartered in Marseille, France, and currently employs approximately 200 people. The business model of Innate Pharma is based on the research and development of immunotherapeutic drugs for various types of cancer and infectious diseases. The company leverages its expertise in the research and utilization of the so-called "innate immune system," which refers to the body's natural defense mechanisms against pathogens and cancer cells. Innate Pharma is active in various business sectors focusing on the development and marketing of therapeutic agents and products. These include: - Oncology: In the field of oncology, the company focuses on the development of drugs that specifically target cancer cells and inhibit cancer growth. Innate Pharma particularly emphasizes the research of antibodies that bind specifically to cancer cells and destroy them. An important product in this area is the medication Lumoxiti, used for the treatment of hairy cell leukemia. - Infectious diseases: In addition to cancer research, Innate Pharma also dedicates itself to the development of therapeutic agents against various infectious diseases. A significant focus here is on viral infections such as COVID-19. The company collaborates closely with various partners and research institutions to identify and develop promising agents. - Autoimmune diseases: Another business sector of Innate Pharma is the research and development of therapies for autoimmune diseases. The company primarily focuses on the use of antibodies and other proteins that aim to selectively influence the immune system and prevent misguided reactions of the body. Innate Pharma has developed and launched a variety of products in recent years. These primarily include therapeutic antibodies that specifically target various structures in the body and activate the body's immune defenses. An important product in this area is the monoclonal antibody IPH4102, used for the treatment of T-cell lymphoma. Innate Pharma collaborates closely with various partners and research institutions to identify and develop promising agents. These include large pharmaceutical companies such as Roche and Bristol-Myers Squibb, as well as innovative start-ups and university hospitals. The close collaboration with the research community aims to ensure that Innate Pharma remains at the forefront of progress and can quickly implement new developments. Like many biotechnology companies, research and development at Innate Pharma are very costly. To finance the development of new therapies, the company relies on cooperation with investors and the issuance of shares. In 2019, Innate Pharma generated a revenue of approximately 47 million euros and incurred a loss of about 55 million euros. However, the company is optimistic about achieving further successes in the coming years and expanding its position as a leading biotechnology company. Innate Pharma is one of the most popular companies on Eulerpool.